Suven Life Sciences: Monitoring Agency Report for Q2 2026
Suven Life Sciences Ltd has submitted its Monitoring Agency (MA) Report for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited. This report, prepared in accordance with SEBI regulations, details the utilization of proceeds from the company's Preferential Issue. The issue size was ₹85,764.02 lakhs, comprising convertible warrants. The report confirms no deviation from the stated objects of the issue. CRISIL Ratings Limited, acting as the Monitoring Agency, has provided an objective view based on information from the issuer and reliable sources, clarifying that they do not perform audits or independent verification.
Key Highlights
- Monitoring Agency Report for Suven Life Sciences for Q2 2026 submitted.
- Report by CRISIL Ratings covers utilization of Preferential Issue proceeds.
- Preferential Issue size was ₹85,764.02 lakhs via convertible warrants.
- No deviation from the objects of the issue was reported.
- CRISIL Ratings provides an objective view, not an audit.
Price Impact
More from SUVEN
Suven Life Sciences Completes Patient Enrollment for Alzheimer's Drug Study
Suven Life Sciences Declares Un-audited Results for Q1 FY27
Consolidated loss widens 148% YoY to ₹127.6 Cr as R&D spend surges on Phase 3 trials